186. Baja jJ.S., Riggio O. Drugtherapy: rifaximin. Hepatology. 2010;52:1484-1488.
187. Kimer N., Krag A., Gluud L. L. Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy. Patient Prefer. Adherence. 2014;8:331-338.
188. Sharma B.C., Sharma P., Lunia M. K., Srivastava S., Goyal R., Sarin S. K. A randomized, double blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am. J. Gastroenterol. 2013;108:1458-1463.
189. Kimer N., Krag A., M0ller S., Bendtsen F., Gluud L. L. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther. 2014 Jul;40(2):123-32. doi: 10.1111/apt.12803. Epub 2014 May 21. PMID: 24849268.
190. World Gastroenterology Organisation Global Guidelines ‘Probiotics and Prebiotics’. 2017 Feb. Available at: http://www. worldgastroenterology.org/guidelines/global guidelines/ probiotics-and-prebiotics/probiotics-and-prebiotics english [Accessed 21 August 2020]
191. Grabherr F., Grander C., Effenberger M., Adolph T. E., Tilg H. Gut Dysfunction and Non-alcoholic Fatty Liver Disease. Frontiers in Endocrinology. 2019;10:611. DOI: 10.3389/ fendo.2019.00611
192. Domenica Maria Di Palo, et al. Increased Colonic Permeability and Lifestyles as Contributing Factors to Obesity and Liver Steatosis. Nutrients. 2020, 12 (2), 564; https://doi.org/10.3390/nu12020564
193. Pang, J., Xu W., Zhang X., et al. Significant positive association of endotoxemia with histological severity in 237 patients with non-alcoholic fatty liver disease. Aliment Pharmacol Th er. 2017; 46: 175-182. https://doi.org/10.1111/ apt.14119
194. Harte A.L., da Silva N. F., Creely S. J. et al. Elevated endotoxin alcoholic in non alhogolic fatty liver disease. J Inflamm. 7, 15 (2010). Doi:10.1186/1476-9255-7-15
195. Hong K.W., Kim K. E., Rhim B. Y., Lee W. S., Kim C. D. Effect of rebamipide on liver damage and increased tumor necrosis factor in a rat model of endotoxin shock. Digestive Diseases and Sciences. 1998 Sep;43(9 Suppl):154S-159S.
196. Sherin Zakaria & Alaa El Sisi Rebamipide retards CCl4-induced hepatic fibrosis in rats: possible role for PGE2. Journal of Immunotoxicology. 2016. 13:4, 453-462, DOI: 10.3109/1547691X.2015.1128022